In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
NIST Center Helps Translate Cyber Standards into Practice
Interagency agreements and the collaboration model at the National Cybersecurity Center of Excellence advance cybersecurity.
15m listen -
DISA Using AI to Secure Multi-Cloud Environments
The Defense Information Systems Agency is harnessing artificial intelligence to secure multi-cloud environments.
13m listen -
How an NCI Data Registry is Helping Diagnose, Treat Rare Pediatric Cancers
The Rare Cancer Initiative is enabling the research community to access more clinical data to improve health outcomes for children diagnosed with rare cancers.
20m listen -
GAO’s Take on Harmonizing Cybersecurity Policy Across Government
Bringing together technology policy requires an “all-of-government” approach, a recent report says.
23m listen
